Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vericel's enterprise value is €1,918.0 Mil.
Vericel's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €27.1 Mil. Therefore, Vericel's EV-to-EBITDA for today is 70.86.
The historical rank and industry rank for Vericel's EV-to-EBITDA or its related term are showing as below:
FRA:ATQP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2481.82 Med: -6.01 Max: 859.77
Current: 69.64
During the past 13 years, the highest EV-to-EBITDA of Vericel was 859.77. The lowest was -2481.82. And the median was -6.01.
FRA:ATQP's EV-to-EBITDA is ranked worse than 86.75% of 400
companies
in the Biotechnology industry
Industry Median: 13.485
vs FRA:ATQP: 69.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vericel's share price for today is €38.40.
Vericel's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vericel's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ATQP vs KLRA, MLYS, NUVB: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Vericel's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vericel's EV-to-EBITDA falls into.
Vericel's current Enterprise Value is €1,918.0 Mil.
Vericel's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €27.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (FRA:ATQP) has a EV-to-EBITDA of 70.86 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vericel. According to the industry distribution chart, Vericel ranks #347 out of 400 companies in the Biotechnology industry, placing it in the top 86.7%.
Is Vericel's EV-to-EBITDA too high?
Vericel's current EV-to-EBITDA is 70.86. The Biotechnology industry median EV-to-EBITDA is 13.49. Vericel's value of 70.86 is 425.5% above this industry median. Based on the distribution chart, Vericel ranks #347 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vericel has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Vericel's EV-to-EBITDA compare to KLRA and MLYS?
According to the Biotechnology industry distribution chart, Vericel ranks #347 out of 400 companies for EV-to-EBITDA. This places Vericel in the lower half of its industry. The industry median EV-to-EBITDA is 13.49. Vericel's value of 70.86 is 425.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.49, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vericel's current EV-to-EBITDA of 70.86 is 425.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vericel. For the Biotechnology industry, the median EV-to-EBITDA is 13.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vericel's current EV-to-EBITDA is 70.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Vericel (FRA:ATQP) has a current EV-to-EBITDA of 70.86. The stock's GF Value™ is €46.17, compared to a current price of €38.40 — trading 16.8% below its estimated fair value. The current EV-to-EBITDA is 70.86 and 425.5% above the Biotechnology industry median of 13.49. Vericel's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vericel (FRA:ATQP), the current EV-to-EBITDA is 70.86 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (FRA:ATQP) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of €38.40 is trading 16.8% below its estimated GF Value™ of €46.17.
Key valuation signals for FRA:ATQP:
EV-to-EBITDA: 70.86
GF Value™: €46.17 vs. price of €38.40 (16.8% below fair value)
Industry Position: 425.5% above the Biotechnology median (#347 of 400)
No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
83GF Score
Get the complete analysis for FRA:ATQP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ATQP has been successfully added to your 
